Bank of America Downgrades Sarepta Therapeutics To Neutral

By: via Benzinga
Bank of America downgraded Sarepta Therapeutics Inc (NASDAQ: SRPT) from Buy to Neutral. The price target for Sarepta Therapeutics has ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.